Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Radiotherapy Shows Benefit in Select Patients With Metastatic Prostate Cancer

January 4th 2019

Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.

Dr. Parker on Radiotherapy in Metastatic Prostate Cancer

January 3rd 2019

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Study Refines Racial Risk Stratification in Prostate Cancer

January 2nd 2019

Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.

Enzalutamide Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

December 21st 2018

Enzalutamide plus androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival compared with ADT alone.

Dr. Morris Discusses Biomarkers in Prostate Cancer

December 17th 2018

Michael J. Morris, MD, medical oncologist, clinical director, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses biomarkers in prostate cancer.

Dr. Gieschen on Patient Selection for Radiation in Prostate Cancer

December 14th 2018

Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses patient selection for radiation in the treatment of prostate cancer.

Enzalutamide/Radium-223 Combo Shows Potential in mCRPC

December 14th 2018

Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

December 13th 2018

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.

Denosumab Safe, Effective in Increasing Bone Density in Nonmetastatic Prostate Cancer

December 11th 2018

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Dr. Vaena on the Importance of Risk Stratification in Prostate Cancer

December 11th 2018

Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder Cancer

December 10th 2018

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.

Dr. Fowke on Overcoming Racial Disparity in Prostate Cancer

December 7th 2018

Jay H. Fowke, PhD, MPH, MS, chief, Division of Epidemiology, professor of preventive medicine, University of Tennessee Health Science Center, discusses ways to overcome racial disparity in prostate cancer.

Dr. Slovin on ADT-Associated Cardiac Complications in Prostate Cancer

December 4th 2018

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses androgen receptor therapy (ADT)-associated cardiac complications in prostate cancer.

San Diego Urology Group Enjoys Growth in a Tough Market

November 30th 2018

Genesis Healthcare Partners, the region’s largest independent urology practice, is challenged by regulatory changes and the dominance of the regional managed care market, which has huge control of patient flow and payment structures.

What Lies Ahead in Urology

November 30th 2018

Raoul S. Concepcion, MD, FACS, discusses considerations for urologists in this new era.

Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer

November 30th 2018

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.

Sifting for Relevance Among Germline Mutations in Prostate Cancer

November 29th 2018

Up to 30% of men with prostate cancer could meet criteria for genetic evaluation for hereditary disease. The challenge is separating the mutations that are relevant from those that are not.

Dr. Bradley on Next Steps for Research in Nonmetastatic Prostate Cancer

November 29th 2018

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

November 29th 2018

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer

November 28th 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.